echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > JCEM: Does rituximab benefit in the treatment of patients with Graves ophthalmopathy?

    JCEM: Does rituximab benefit in the treatment of patients with Graves ophthalmopathy?

    • Last Update: 2021-09-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Graves' ophthalmopathy (GO) is a potentially vision-threatening disease that cannot be successfully treated with existing drugs


    Threatening eyesight

    Objective: To study the efficacy of rituximab (RTX) in the treatment of GO


    Purpose:

    Method : This is a prospective, randomized, double-blind, placebo case-control trial


    Method :

    Intervention: Two intravenous RTX infusions (1000 mg each time) or two saline infusions every 2 weeks


    Intervention:

    MAIN OUTCOME MEASURE: The primary endpoint is the continuous decline of the clinical activity score (CAS), and the improvement was ≥2 points at 24 weeks


    MAIN OUTCOME MEASURE: The clinical activity score (CAS) decreased continuously and improved by ≥2 points at 24 weeks

    Secondary endpoints : including success rate and failure rate, the proportion of clinically significant improvement of prominent symptoms, eye cleft width, diplopia score, exophthalmos and disease severity, as well as changes in these parameters, periorbital fat/muscle volume, and quality of life


    Secondary endpoint :

    Results: All parameters in the treatment group were similar at baseline


    result:

    Figure 1 Changes in CAS and TRAb levels during the study.


    Figure 1 Changes in CAS and TRAb levels during the study.


    (C) The average CAS±SD of each group; (D) The median level of TRAb in each group


    (5 patients stopped before or after the 24th week) or 52 weeks (individual patients stopped the trial after 24 weeks) for final evaluation


    Table 1 Changes in disease parameters; Abbreviations: TOV, total eyeball volume; TMV, total muscle volume; TFV, total fat


    Table 1 Changes in disease parameters; Abbreviations: TOV, total eyeball volume; TMV, total muscle volume; TFV, total fat


    Figure 2 In each study group, the proportion of patients with clinically significant improvement from baseline to 24 weeks (A and B) or from baseline to 52 weeks (C and D)


    Figure 2 In each study group, the proportion of patients with clinically significant improvement from baseline to 24 weeks (A and B) or from baseline to 52 weeks (C and D)


    Exophthalmos ≥2mm; diplopia score from 3 or 4 to 0, 1 or 2; eye cleft width ≥3mm; NOSPECS is classified according to 1 or 2 categories (A and C)


    No need for additional treatment (success) or CAS reduction <2 points or need for additional treatment (failure)
    .
    There was no significant difference between any parameter group at any time point in each study group
    .

    Table 2 Side effects; bold numbers indicate moderate/severe side effects

    Table 2 Side effects; bold numbers indicate moderate/severe side effects

    Conclusion: Compared with placebo, RTX on activity and moderate to severe GO patients without extra good at, and there are not able to ignore visual adverse reactions
    .

    Conclusion: Compared with placebo, RTX on activity and moderate to severe GO patients without extra good at, and there are not able to ignore visual adverse reactions
    .

    Original source

    Stan MN, Garrity JA, Carranza Leon BG, Randomized controlled trial of rituximab in patients with Graves' orbitopathy .
    J Clin Endocrinol Metab 2015 Feb;100(2)

    Randomized controlled trial of rituximab in patients with Graves' orbitopathy

    in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.